肺動脈高血圧（PAH）の世界市場分析：薬の問題別（プロスタサイクリンおよびプロスタサイクリンアナログ、可溶性グアニル酸シクラーゼ（SGC）刺激薬、エンドセリン受容体アンタゴニスト（ERA）、ホスホジエステラーゼ5（PDE-5）、セグメント予測、2014-2025...市場調査レポートについてご紹介

Table of Content

Chapter 1 Research Methodology
1.1 Research Methodology
1.2 Research Scope & Assumptions
1.3 List of Data Sources
Chapter 2 Executive Summary
Chapter 3 Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.2 Market Driver Analysis
3.3 Market Restraint Analysis
3.4 Penetration & Growth Prospect Mapping
3.5 SWOT Analysis, By Factor
3.5.1 Political
3.5.2 Economic
3.5.3 Technology
Chapter 4 Market Categorization 1: Drug Class Estimates & Trend Analysis
4.1 Drug Class Movement Analysis & Market Share, 2014 & 2024
4.2 Market Size & Forecasts and Trend Analyses, 2014 to 2024 For the Following Drug Class:
4.2.1 Prostacyclin and Prostacyclin Analogs
4.2.2 SGC Stimulators
4.2.3 ERA
4.2.4 PDE-5
Chapter 5 Market Categorization 2: Regional Estimates & Trend Analysis
5.1 Regional Movement Analysis & Market Share, 2015 & 2025
5.2 Market Size & Forecasts and Trend Analyses, 2014 to 2025 for the following regions:
5.2.1 North America
5.2.1.1 U.S.
5.2.1.2 Canada
5.2.2 Europe
5.2.2.1 UK
5.2.2.2 Germany
5.2.3 Asia Pacific
5.2.3.1 Japan
5.2.3.2 China
5.2.4 Latin America
5.2.4.1 Brazil
5.2.4.2 Mexico
5.2.5 MEA
5.2.5.1 South Africa
Chapter 6 Competitive Landscape
6.1 Strategy Framework
6.2 Company Profiles
6.2.1 Actelion Pharmaceuticals, Ltd
6.2.1.1 Company overview
6.2.1.2 Financial performance
6.2.1.3 Product benchmarking
6.2.1.4 Strategic initiatives
6.2.2 Gilead Sciences, Inc
6.2.2.1 Company overview
6.2.2.2 Financial performance
6.2.2.3 Product benchmarking
6.2.2.4 Strategic initiatives
6.2.3 United Therapeutics Corporation
6.2.3.1 Company overview
6.2.3.2 Financial performance
6.2.3.3 Product benchmarking
6.2.3.4 Strategic initiatives
6.2.4 Novartis International AG
6.2.4.1 Company overview
6.2.4.2 Financial performance
6.2.4.3 Product benchmarking
6.2.4.4 Strategic initiatives
6.2.5 GlaxoSmithKline Plc. (GSK)
6.2.5.1 Company overview
6.2.5.2 Financial performance
6.2.5.3 Product benchmarking
6.2.5.4 Strategic initiatives
6.2.6 Pfizer, Inc
6.2.6.1 Company overview
6.2.6.2 Financial performance
6.2.6.3 Product benchmarking
6.2.6.4 Strategic initiatives
6.2.7 Dong-A ST Co., Ltd.
6.2.7.1 Company overview
6.2.7.2 Financial performance
6.2.7.3 Product benchmarking
6.2.7.4 Strategic initiatives
6.2.8 Merck Sharp & Dohme Corp
6.2.8.1 Company overview
6.2.8.2 Financial performance
6.2.8.3 Product benchmarking
6.2.8.4 Strategic initiatives
6.2.9 Bayer HealthCare
6.2.9.1 Company overview
6.2.9.2 Financial performance
6.2.9.3 Product benchmarking
6.2.9.4 Strategic initiatives
6.2.10 Arena Pharmaceuticals
6.2.10.1 Company overview
6.2.10.2 Financial performance
6.2.10.3 Product benchmarking
6.2.10.4 Strategic initiatives